Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100) - Image 1

£140.51

Springer Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100)

Name: Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100)
Brand: Springer
Price: 140.51 GBP
Availability: InStock

Cardiovascular

Price History & Forecast

Last 39 days • 39 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 39 days • 1 price levels

Days at Price

Price Analysis

Most common price: £141 (39 days, 100.0%)

Price range: £141 - £141

Price levels: 1 different prices over 39 days

Description

The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies.

Product Specifications

Brand: Springer
Format: paperback
ASIN: 1461288886
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Cardiovascular
Domain: Amazon UK
Publication Date: 10 October 2011
Listed Since: 21 December 2012

Barcode

No barcode data available

Springer Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100)

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents: Proceedings of the Ninth Annual Symposium on ... in Cardiovascular Medicine, 100)

Springer - Sudden Cardiac Death and Congestive Heart Failure

Springer - Sudden Cardiac Death and Congestive Heart Failure

Antithrombotic Drug Therapy in Cardiovascular Disease (Contemporary Cardiology)

Springer Cardiac Arrhythmias - New Drugs and Devices Book

The Modern Era of Coronary Thrombolysis: 160 (Developments in Cardiovascular Medicine, 160)

Early Interventions in Acute Myocardial Infarction: 97 (Developments in Cardiovascular Medicine)

The Modern Era of Coronary Thrombolysis: 160 (Developments in Cardiovascular Medicine, 160)

CRC Press Clinical Guide to Antithrombotic Drugs in CAD

Pharmacological Aspects of Heart Disease: Proceedings of an International Symposium on Heart Metabolism in Health and Disease and the Third Annual ... (Developments in Cardiovascular Medicine, 68)

Early Interventions in Acute Myocardial Infarction: 97 (Developments in Cardiovascular Medicine, 97)

Coronary Artery Disease: Therapeutics and Drug Discovery: 1177 (Advances in Experimental Medicine and Biology, 1177)

Antiarrhythmic Drugs (Current Cardiovascular Therapy)

Myocardial Ischemia and Arrhythmia: Under the auspices of the Society of Cooperation in Medicine and Science (SCMS), Freiburg, Germany

Antiarrhythmic Drugs: 89 (Handbook of Experimental Pharmacology, 89)

Tachycardia: Risk Factors, Causes & Treatment Options (Cardiology Research and Clinical Developments)

XIVth International Symposium on Medicinal Chemistry: Proceedings : Maastricht, the Netherlands, 8-12 September 1996 (Pharmacochemistry Library): Volume 28

Triggering of Acute Coronary Syndromes: Implications for Prevention: 170 (Developments in Cardiovascular Medicine, 170)

Fibrinogen, Thrombosis, Coagulation and Fibrinolysis: International Symposium Proceedings: 281 (Advances in Experimental Medicine and Biology)

Clinical Applications of Cardiovascular Drugs: 5 (Developments in Cardiovascular Medicine, 5)

Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease (Contemporary Cardiology)

Humana Anticoagulants, Antiplatelets, and Thrombolytics - 663

Cardiovascular Thrombus: From Pathology and Clinical Presentations to Imaging, Pharmacotherapy and Interventions

Clopidogrel and the Newer P2Y12 Antiplatelet Agents: Pharmacology, Clinical Uses, and Adverse Effects